Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia 21-09-2024, 15:15

Notice of Filing Securities Class Action Against Global 10-02-2023, 02:38

Československá obchodní banka (CSOB) Selects the nCino Platform to Modernize Commercial & SME Lending 11-03-2025, 14:30